Chugai Pharmabody Research Pte. Ltd. ('CPR') was established in Singapore as a wholly-owned subsidiary of Chugai Pharmaceutical Co., Ltd (Chugai), a member of Roche group, in January 2012 and started operations on July 2, 2012. Located at Biopolis in Singapore , it aims to generate new antibody drugs based on Chugai's proprietary antibody engineering technologies, such as recycling antibody®, sweeping antibody®, bispecific antibody, various Fc engineered antibodies, and other new antibody engineering technologies that are under development.

Position - Research Assistant in Cell Biology and Technology Unit

Job Scope:

. Tool generation - expression vector construction and molecular cloning, protein expression, stable cell lines development

. Drug screening - ELISA, FACS, cell-based functional assay, confocal microscopy, SDS-PAGE, Western Blotting, qPCR etc.

...